SCHEMBL5871813

SCHEMBL5871813

COc1ccc2c(c1)N(C1CCN(Cc3ccccc3)CC1)CC2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 7/20 0.53
CHRM3 P20309 4/20 0.53
HTR2C P28335 2/20 0.53
HTR2B P41595 2/20 0.53
DRD2 P14416 1/20 0.53
HTR2A P28223 1/20 0.53
ACHE P22303 4/20 0.52
BACE1 P56817 2/20 0.52
CHRM2 P08172 3/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
ALDH1A1 P00352 1/20 0.49
HTR1A P08908 1/20 0.49
DRD4 P21917 1/20 0.49
ADRA1D P25100 1/20 0.49
ADRA1A P35348 1/20 0.49
ADRA1B P35368 1/20 0.49
DRD3 P35462 1/20 0.49
SLC6A3 Q01959 1/20 0.49
TMEM97 Q5BJF2 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5871862 0.93 ACHE (0.50) SIGMAR1CHRM3HTR2CHTR2BDRD2
SCHEMBL3654185 0.82 DRD2 (0.65) SIGMAR1CHRM3HTR2CHTR2BDRD2
SCHEMBL5871503 0.82 MBTD1 (0.48) SIGMAR1CHRM3DRD2ACHECHRM2
SCHEMBL5871208 0.82 ALDH1A1 (0.52) SIGMAR1CHRM3HTR2CHTR2BDRD2
SCHEMBL5871015 0.81 SIGMAR1 (0.55) SIGMAR1HTR2CHTR2BHTR1A
SCHEMBL5871409 0.81 DRD2 (0.47) CHRM3DRD2ACHECHRM2DRD4
SCHEMBL2262403 0.81 CHRM3 (0.57) SIGMAR1CHRM3HTR2CHTR2BDRD2
SCHEMBL5871336 0.80 DRD2 (0.55) CHRM3DRD2ACHECHRM2DRD4
SCHEMBL7846425 0.79 SIGMAR1 (0.65) SIGMAR1CHRM3HTR2CHTR2BDRD2
SCHEMBL4073208 0.78 HTR1A (0.55) SIGMAR1HTR2CHTR2BMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7071201-B2 Serotonin antagonism; muscle relaxant for myotonia; such as 1-(1-(2-(4-methoxyphenyl)ethyl)piperidin-4-yl)-7-methoxy-1,2,3,4 -tetrahydroquinoline EISAI CO., LTD. (JP) 2006-07-04 US disclosed
EP-0976732-B1 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES EISAI CO LTD (JP) 2004-11-24 EP disclosed
US-6579881-B2 Indoles EISAI CO., LTD. (JP) 2003-06-17 US disclosed
US-6448243-B1 SEROTONIN ANTAGONIST FOR TREATING, AMELIORATING AND PREVENTING SPASTIC PARALYSIS OR CENTRAL MUSCLE RELAXANTS FOR AMELIORATING MYOTONIA EISAI CO., LTD. (JP) 2002-09-10 US disclosed
US-20020086999-A1 Certain quinoline derivatives EISAI CO., LTD. 2002-07-04 US disclosed
US-20020019531-A1 Indoles EISAI CO., LTD. 2002-02-14 US disclosed
EP-0976732-A1 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES Eisai Co., Ltd. (JP) 2000-02-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019531-A1 Indoles INMT, MUSK, MB SIGMAR1 1200/4885CHRM3 146/4885HTR2C 222/4885
US-20020086999-A1 Certain quinoline derivatives CHRM1, CHRNA5, CHRNA4 SIGMAR1 523/4885CHRM3 25/4885HTR2C 107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.